http://ift.tt/1sHX1gh
Health policy analysts across the globe have declared that pharmaceutical R&D investments are becoming less productive over time. In contrast, investors that fund these R&D investments are posting increasing valuations of the same companies. This conflict can be resolved when productivity is measured in ways that matter to patients and thereby generate the increased earnings supporting larger valuations. New evidence from the University of Chicago suggests that previous measures miss half the story and that R&D productivity has risen, not fallen, over time.
from Forbes Real Time http://onforb.es/19QgXWs
Health policy analysts across the globe have declared that pharmaceutical R&D investments are becoming less productive over time. In contrast, investors that fund these R&D investments are posting increasing valuations of the same companies. This conflict can be resolved when productivity is measured in ways that matter to patients and thereby generate the increased earnings supporting larger valuations. New evidence from the University of Chicago suggests that previous measures miss half the story and that R&D productivity has risen, not fallen, over time.
from Forbes Real Time http://onforb.es/19QgXWs
